53 related articles for article (PubMed ID: 38656636)
21. Possible Role of Circulating Tumour Cells for Prediction of Salvage Lymph Node Dissection Outcome in Patients with Early Prostate Cancer Recurrence.
Knipper S; Riethdorf S; Werner S; Tilki D; Graefen M; Pantel K; Maurer T
Eur Urol Open Sci; 2021 Dec; 34():55-58. PubMed ID: 34786563
[TBL] [Abstract][Full Text] [Related]
22. Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
Tsuzuki S; Kawano S; Fukuokaya W; Mori K; Nishikawa H; Tashiro K; Watanabe D; Uchimoto T; Nishimura K; Yano Y; Murakami M; Koike Y; Hata K; Koide H; Miki J; Abe H; Yamada H; Naruoka T; Sugaya S; Kimura T; Tomita M; Nakajo H; Egawa S
Jpn J Clin Oncol; 2021 Nov; 51(11):1665-1671. PubMed ID: 34296282
[TBL] [Abstract][Full Text] [Related]
23. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine and Aggressive-Variant Prostate Cancer.
Spetsieris N; Boukovala M; Patsakis G; Alafis I; Efstathiou E
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33339136
[TBL] [Abstract][Full Text] [Related]
25. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.
Li F; Xiang H; Pang Z; Chen Z; Dai J; Chen S; Xu B; Zhang T
Cancer Med; 2020 Oct; 9(19):7341-7351. PubMed ID: 32452656
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
27. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
Hofman MS; Lawrentschuk N; Francis RJ; Tang C; Vela I; Thomas P; Rutherford N; Martin JM; Frydenberg M; Shakher R; Wong LM; Taubman K; Ting Lee S; Hsiao E; Roach P; Nottage M; Kirkwood I; Hayne D; Link E; Marusic P; Matera A; Herschtal A; Iravani A; Hicks RJ; Williams S; Murphy DG;
Lancet; 2020 Apr; 395(10231):1208-1216. PubMed ID: 32209449
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of alkaline phosphatase in hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Mori K; Janisch F; Parizi MK; Mostafaei H; Lysenko I; Enikeev DV; Kimura S; Egawa S; Shariat SF
Int J Clin Oncol; 2020 Feb; 25(2):247-257. PubMed ID: 31768692
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Kimura S; Parizi MK; Enikeev DV; Glybochko PV; Seebacher V; Fajkovic H; Mostafaei H; Lysenko I; Janisch F; Egawa S; Shariat SF
Clin Genitourin Cancer; 2019 Dec; 17(6):409-418. PubMed ID: 31558410
[TBL] [Abstract][Full Text] [Related]
30. Use of machine learning to predict early biochemical recurrence after robot-assisted prostatectomy.
Wong NC; Lam C; Patterson L; Shayegan B
BJU Int; 2019 Jan; 123(1):51-57. PubMed ID: 29969172
[TBL] [Abstract][Full Text] [Related]
31. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.
Heinrich D; Bruland Ø; Guise TA; Suzuki H; Sartor O
Future Oncol; 2018 Oct; 14(24):2543-2556. PubMed ID: 29925281
[TBL] [Abstract][Full Text] [Related]
32.
Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
[TBL] [Abstract][Full Text] [Related]
33. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature.
Muoio B; Pascale M; Roggero E
Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659
[TBL] [Abstract][Full Text] [Related]
34. Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers.
Nan J; Li J; Li X; Guo G; Wen X; Tian Y
Biomark Cancer; 2017; 9():1-7. PubMed ID: 28469484
[TBL] [Abstract][Full Text] [Related]
35. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
36. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
37. Current use of PSMA-PET in prostate cancer management.
Maurer T; Eiber M; Schwaiger M; Gschwend JE
Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
[TBL] [Abstract][Full Text] [Related]
38. Platinum-based chemotherapy for variant castrate-resistant prostate cancer.
Aparicio AM; Harzstark AL; Corn PG; Wen S; Araujo JC; Tu SM; Pagliaro LC; Kim J; Millikan RE; Ryan C; Tannir NM; Zurita AJ; Mathew P; Arap W; Troncoso P; Thall PF; Logothetis CJ
Clin Cancer Res; 2013 Jul; 19(13):3621-30. PubMed ID: 23649003
[TBL] [Abstract][Full Text] [Related]
39. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.
Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Fizazi K
Ann Oncol; 2009 Apr; 20(4):703-8. PubMed ID: 19179557
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
